uniQure QURE 深 沪
已收盘 09-06 16:00:00 美东时间
5.42
-0.110
-1.99%
华盛通- 最 高5.555
- 今 开5.53
- 成交量 30.20万股
- 最 低 5.28
- 昨 收 5.53
- 总市值 2.59亿
- 52周最高 11.35
- 市盈率 静 --
- 换手率 0.63%
- 52周最低 3.73
- 委 比 86.77%
- 总股本 4778.13万
- 历史最高 82.49
- 量 比 0.69
- 振 幅 4.97%
- 历史最低 3.73
- 每 手 1
- 风险率 1.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多uniQure Begins Phase I/IIa Trial for Fabry Disease Treatment
uniQure (QURE) has shared an announcement. uniQure N.V. has reached a significa...
08-15 20:22
UniQure to cut 65% of workforce, or 300 jobs, in major restructuring
UniQure (NASDAQ:QURE) said it is cutting its workforce by 65%, or 300 positions, as part of a major company restructuring to conserve capital and extend its cash runway. In its Q2 earnings report rele...
08-03 03:47
uniQure Advances with Strategic Facility Sale and Partnership Deals
uniQure (QURE) has issued an announcement. On July 22, 2024, uniQure completed ...
07-23 19:28
UniQure (NASDAQ:QURE) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu,...
07-12 21:04
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after ...
07-12 02:02
Why Are UniQure Shares Surging Today?
UniQure N.V. (NASDAQ: QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's disease.
07-11 04:00
美股牛股 | 基因治疗公司uniQure飙升76.5%；陆金所升近19%，平安增持股份市场信心增强
基因治疗公司uniQure飙升76.5%，公司的AMT-130临床试验积极结果提振市场信心；陆金所升近19%，中国平安被动并表陆控持股比例将升至56.82%>>
07-10 19:52
uniQure updates trial data for Huntington’s disease therapy
uniQure (NASDAQ:QURE) shares traded higher premarket Tuesday after the Dutch biotech posted the latest data from its Phase 1/2 clinical trials for AMT-130, an investigational gene therapy for Huntingt...
07-09 19:45
uniQure’s AMT-130 Shows Promise in Huntington’s Treatment Trials
uniQure (QURE) has provided an update. uniQure N.V. has released promising inte...
07-09 19:28
UniQure's Huntington's Disease Gene Therapy Shows Interim Results at 24 Months
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transforma...
07-09 19:09
